Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Cancer Investigation|April 4, 2012
A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancerChristian Dittrich, Ewa Solska, Alexey Manikhas, et al.
Pharmaceutical Research|October 28, 2018
Correction to: Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy SubjectsSravanthi Cheeti, Hao Helen Hou, Eric Nelson, et al.
Pharmaceutical Research|October 17, 2018
Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy SubjectsSravanthi Cheeti, Hao Helen Hou, Eric Nelson, et al.
Cancer Chemotherapy and Pharmacology|September 15, 2015
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumorsKelong Han, Jin Y Jin, Mathilde Marchand, et al.
Epilepsy Research|March 21, 2009
Safety of an IV formulation of carbamazepineJeannine M Conway, James R White, Angela K Birnbaum, et al.
Neuro-Oncology|February 17, 2010
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I studyNicholas Butowski, Susan M Chang, Kathleen R Lamborn, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 31, 2023
The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) InhibitorRyan H Takahashi, Vikram Malhi, Bianca M Liederer, et al.
Investigational New Drugs|August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 10, 2015
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in HumansRyan H Takahashi, Edna F Choo, Shuguang Ma, et al.
Anti-Cancer Drugs|November 29, 2007
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumorsD Ross Camidge, S Gail Eckhardt, Lia Gore, et al.
Pageof 5